Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling

Author:

Zhou Xiaoxiao1ORCID,Zou Haotian1,Lutz Michael W.2,Arbeev Konstantin3,Akushevich Igor3,Yashin Anatoli3,Welsh‐Bohmer Kathleen A.45,Luo Sheng1ORCID

Affiliation:

1. Department of Biostatistics & Bioinformatics Duke University Durham North Carolina USA

2. Division of Translational Brain Sciences Department of Neurology Duke University Medical Center Durham North Carolina USA

3. Social Science Research Institute Duke University Durham North Carolina USA

4. Department of Psychiatry Duke University Durham North Carolina USA

5. Duke Clinical Research Institute (DCRI) Duke University Durham North Carolina USA

Abstract

AbstractINTRODUCTIONAlzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations.METHODSLongitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early‐stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities.RESULTSWe observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities.DISCUSSIONWhile tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories.Highlights Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early‐stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models. Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression. Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD. Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time‐dependent random effects and data‐driven IRT models.

Funder

National Institute on Aging

Publisher

Wiley

Reference35 articles.

1. Alzheimer's disease

2. The Clinical Dementia Rating (CDR)

3. Greater Precision when Measuring Dementia Severity: Establishing Item Parameters for the Clinical Dementia Rating Scale

4. Health UDo Services H.Guidelines for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease.2013.

5. Health UDo Services H.Early Alzheimer's Disease: Developing Drugs For Treatment Guidelines for Industry.2018.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3